Search research articles
Contact Us
Filters
Showing results (71-80 of 129) with videos related to
Page
of 13
Sort By:
Future Oncology (London, England)
|
November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Pathology
|
March 18, 2025
Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia
Wendy A Cooper, Benhur Amanuel, Caroline Cooper, et al.
Clinical Pharmacokinetics
|
December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
Future Oncology (London, England)
|
September 28, 2023
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue
Antony J Mersiades, Benjamin J Solomon, David M Thomas, et al.
Investigational New Drugs
|
May 20, 2024
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Science Translational Medicine
|
January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 10, 2025
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
Marliese Alexander, Malinda Itchins, Jonathan Felthun, et al.
Investigational New Drugs
|
February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
Solange Peters, Alice T Shaw, Benjamin Besse, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 129) with videos related to
Sort By:
Page
of 13
Future Oncology (London, England)
|
November 5, 2020
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, et al.
Pathology
|
March 18, 2025
Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia
Wendy A Cooper, Benhur Amanuel, Caroline Cooper, et al.
Clinical Pharmacokinetics
|
December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
Joseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
Future Oncology (London, England)
|
September 28, 2023
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue
Antony J Mersiades, Benjamin J Solomon, David M Thomas, et al.
Investigational New Drugs
|
May 20, 2024
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Science Translational Medicine
|
January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
Ryohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 10, 2025
Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis
Marliese Alexander, Malinda Itchins, Jonathan Felthun, et al.
Investigational New Drugs
|
February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
Solange Peters, Alice T Shaw, Benjamin Besse, et al.
Page
of 13